GeoVax Labs Inc. (GOVX) Opens Third Site for HIV/AIDS Vaccine Testing

QualityStocks would like to highlight GeoVax Labs (OTCBB: GOVX), a biotechnology company developing human vaccines for diseases caused by HIV (Human Immunodeficiency Virus – that leads to AIDS). The company’s goals include developing HIV/AIDS vaccines for global markets, overseeing the manufacture and testing these vaccines under GMP/GLP conditions (FDA guidelines), conducting clinical trials for vaccine safety and effectiveness, and obtaining regulatory approvals to move the product forward.

In the company’s news today,

GeoVax Labs announced it has opened a third site for testing the therapeutic potential of its HIV/AIDS vaccine in conjunction with the AIDS Research Alliance, the nation’s only independent, nonprofit research institute dedicated to the search for a cure for AIDS.

The Los Angeles-based ARA will team up with two existing members of GeoVax’s clinical trial site team, the AIDS Research Consortium of Atlanta and the Alabama Vaccine Research Clinic at the University of Alabama at Birmingham.

The therapeutic trial marks the first trial designed to test GeoVax’s vaccine as a possible treatment for HIV. The upcoming clinical trial will test safety, vaccine-induced immune responses, and the ability of the vaccine to control viral replication in HIV-infected patients.

GeoVax said previous studies involving simian prototypes of the vaccine in infected non-human primates demonstrated the vaccine’s ability to control viral replication in the absence of anti-viral drugs.

“We are excited to expand our therapeutic trial team to include the AIDS Research Alliance,” Mark Newman, PhD, vice president of Research and Development at GeoVax stated in the press release. “They are a group with a mission that parallels that of GeoVax, developing a vaccine to prevent infection by HIV and developing better treatments for those who become infected.”

Dr. Stephen Brown, ARA’s medical director, said that the development of new products and approaches that springing from existing antiretroviral drugs regimens would represent a major breakthrough in AIDS research.

GeoVax’s vaccines are currently being tested in HIV-uninfected persons in a phase II clinical trial by the HIV Vaccine Trials Network (HVTN), which are funded by the National Institute of Allergy and Infectious Diseases, a division of the National Institutes of Health.

About QualityStocks

QualityStocks, based in Scottsdale, Arizona, is a free service that collects data from hundreds of Small-Cap and Micro-Cap online Investment Newsletters into one Daily Newsletter Report. QualityStocks is dedicated to assisting emerging public companies with their investor communication efforts and connecting subscribers with companies that have huge potential to succeed in the short and long-term future.

To sign up for “The QualityStocks Daily Newsletter” please visit www.QualityStocks.net

Please see disclaimer on QualityStocks website: http://Disclaimer.QualityStocks.net

Forward-Looking Statement:

This release may contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All forward-looking statements are inherently uncertain as they are based on current expectations and assumptions concerning future events or future performance of the company. Readers are cautioned not to place undue reliance on these forward-looking statements, which are only predictions and speak only as of the date hereof. Risks and uncertainties applicable to the company and its business could cause the company's actual results to differ materially from those indicated in any forward-looking statements.